Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.
Hing ZA, Fung HY, Ranganathan P, Mitchell S, El-Gamal D, Woyach JA, Williams K, Goettl VM, Smith J, Yu X, Meng X, Sun Q, Cagatay T, Lehman AM, Lucas DM, Baloglu E, Shacham S, Kauffman MG, Byrd JC, Chook YM, Garzon R, Lapalombella R.
Hing ZA, et al. Among authors: ranganathan p.
Leukemia. 2016 Dec;30(12):2364-2372. doi: 10.1038/leu.2016.136. Epub 2016 May 20.
Leukemia. 2016.
PMID: 27323910
Free PMC article.